On Thursday, Shares of Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), surged 22.25% to $5.
Eleven Biotherapeutics declared dose administration for the first patients in a Phase 3 study of EBI-005 for the treatment of moderate to severe allergic conjunctivitis. This Phase 3 study was designed and initiated following the completion in October 2014 of a Phase 2 study in which EBI-005 exhibited biological activity in improving the symptoms of late-phase allergic responses in patients with moderate to severe allergic conjunctivitis. This comprised of statistically noteworthy improvements in mean change from baseline in patient stated ocular itching, tearing and associated nasal symptoms contrast to vehicle-control at the second to last and final assessment time points following allergen exposure in a modified direct conjunctival allergen provocation test (CAPT) model.
Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States.
Shares of Noble Corporation plc (NYSE:NE), declined -6.10% to $12.78, during its last trading session.
On July 29, Noble Corporation stated second quarter 2015 net income attributable to Noble Corporation of $159 million, or $0.64 per diluted share. The results contrast to net income attributable to Noble Corporation in the first quarter of 2015 of $178 million, or $0.72 per diluted share. For the second quarter of 2014, net income from ongoing operations attributable to Noble Corporation was $140 million, or $0.54 per diluted share. Revenues for the second quarter of 2015 totaled $794 million contrast to revenues of $804 million in both the first quarter of 2015 and second quarter of 2014.
Net cash from operating activities totaled $399 million in the second quarter of 2015 and $768 million for the six months ended June 30, 2015, while capital expenditures in the second quarter were $81 million and totaled $170 million through June 30, 2015. The Company has reduced its predictable 2015 capital expenditures by $60 million, to $525 million following further cost administration initiatives and revised timing for certain expenditures pertaining to major projects.
Noble Corporation plc operates as an offshore drilling contractor for the oil and gas industry worldwide. It owns and operates a fleet of mobile offshore drilling units.
Finally, Staples, Inc. (NASDAQ:SPLS), ended its last trade with -0.56% loss, and closed at $14.08.
Staples declared that it has received clearance from the Australian Competition and Consumer Commission for the acquisition of Office Depot. Staples continues to seek clearance from regulatory agencies in the United States, the European Union and Canada.
The Commerce Commission of New Zealand and the Ministry of Commerce of the People’s Republic of China formerly gave their clearance for the transaction in June.
“We continue to make progress on this transaction, and we’re happy with this decision by the Australian Competition and Consumer Commission,” said Ron Sargent, Chairman and Chief Executive Officer, Staples, Inc. “We continue to work closely with regulatory agencies around the world and expect the transaction to be accomplished by the end of the year.”
Staples, Inc., together with its auxiliaries, operates office products superstores. It operates through three segments: North American Stores & Online, North American Commercial, and International Operations.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
